William M Byra
Overview
Explore the profile of William M Byra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferreira J, Cleland J, Lam C, Anker S, Mehra M, Van Veldhuisen D, et al.
Clin Res Cardiol
. 2021 Jun;
111(1):50-59.
PMID: 34128083
Background: Atrial fibrillation (AF) in the presence of heart failure (HF) is associated with poor outcomes including a high-risk of stroke and other thromboembolic events. Identifying patients without AF who...
2.
Ferreira J, Cleland J, Lam C, Anker S, Mehra M, Van Veldhuisen D, et al.
Clin Res Cardiol
. 2021 Mar;
110(10):1554-1563.
PMID: 33686472
Background: Patients with coronary artery disease (CAD) are at increased risk of developing and being hospitalised for heart failure (HFH). However, the risk of HFH versus ischemic events may vary...
3.
Ferreira J, Cleland J, Lam C, Van Veldhuisen D, Byra W, La Police D, et al.
JACC Heart Fail
. 2021 Feb;
9(3):201-211.
PMID: 33549557
Objectives: This study sought to compare patient characteristics, outcomes, and treatment effects among regions in the COMMANDER-HF trial. Background: Globalization of cardiovascular trials increases generalizability. However, regional differences may also...
4.
Ferreira J, Lam C, Anker S, Mehra M, Van Veldhuisen D, Byra W, et al.
Eur J Heart Fail
. 2020 Sep;
23(4):648-656.
PMID: 32959502
Aims: D-dimer is a marker of fibrin degradation that reflects intravascular coagulation. Therefore, plasma concentrations of D-dimer might predict thromboembolic risk and rivaroxaban treatment effect. The aims of this study...
5.
Cunningham J, Ferreira J, Deng H, Anker S, Byra W, Cleland J, et al.
JACC Heart Fail
. 2020 Mar;
8(5):359-368.
PMID: 32171760
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevated natriuretic peptides for inclusion in the COMMANDER-HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban...
6.
Mehra M, Vaduganathan M, Fu M, Ferreira J, Anker S, Cleland J, et al.
Eur Heart J
. 2019 Aug;
40(44):3593-3602.
PMID: 31461239
Aims: Stroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first...
7.
Greenberg B, Neaton J, Anker S, Byra W, Cleland J, Deng H, et al.
JAMA Cardiol
. 2019 Apr;
4(6):515-523.
PMID: 31017637
Importance: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is uncertain. The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy...
8.
Zannad F, Anker S, Byra W, Cleland J, Fu M, Gheorghiade M, et al.
N Engl J Med
. 2018 Aug;
379(14):1332-1342.
PMID: 30146935
Background: Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and...
9.
Zannad F, Greenberg B, Cleland J, Gheorghiade M, Van Veldhuisen D, Mehra M, et al.
Eur J Heart Fail
. 2015 Apr;
17(7):735-42.
PMID: 25919061
Aims: Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety...